We are greatful to have David J. Mazzo, PhD, President & CEO of Lisata Therapeutics, Inc. (NASDAQ: LSTA) here with us in this episode of CEO Interview . He sat down with us to introduce their key product, Certepetide (LSTA1), and mentioned some of the Q1 financial highlights. At the end of the interview, he also shared about company’s upcoming milestones in the next 12 months.
About Lisata Therapeutics, Inc. (NASDAQ: LSTA)
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.
Lisata’s lead product candidate, certepetide (formerly LSTA1), is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively.
Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next two years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. For more information, please visit the website.
CEO Interview series is a program where we invite CEOs or senior executives of public companies with great growth potential. We will present investing ideas across different sectors, which helps investors to gain quicker and easier access to the most recent developments of these companies.
Disclaimer: NAI is being compensated for this content. Materials contained in this content are for information purposes only and is not intended to constitute an offering of securities in any jurisdiction. Nothing on this content should be construed as an offer, solicitation or recommendation to buy or sell products or securities.
